In February 2014, Mitodys Therapeutics successfully raised £150,000 to fund the initial optimisation and validation of its drug-discovery platform through initial drug prototypes.
MitoDys is a drug-discovery platform, working on a novel approach to treating Parkinson's disease.
MitoDys is headed up by founder Steven Zimmer and a world-class board of scientific and clinical advisors led by Dr David Weiner, a clinician scientist who is a noted expert in Parkinson’s disease, along with a network of academic laboratories and partner CROs.
The lead investor in this round was The Life Neurological Research Trust.
**Where are they now? **
We caught up with Mitodys at our event in April and found out about the company's progress: